Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18924713 | 0.85 | CA2 (0.41) | CA2CA1USP2TSHRMAPK1 | |
| SCHEMBL13448612 | 0.84 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL6893921 | 0.84 | CA2 (0.38) | CA2CA1USP2TSHRMAPK1 | |
| SCHEMBL10875904 | 0.79 | CA2 (0.38) | CA2CA1USP2TSHRMAPK1 | |
| SCHEMBL14991049 | 0.78 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL684789 | 0.78 | TSHR (0.43) | CA2CA1USP2TSHRMAPK1 | |
| SCHEMBL18856283 | 0.77 | SMN1; SMN2 (0.36) | CA2CA1TSHRALDH1A1 | |
| SCHEMBL4450340 | 0.76 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| SCHEMBL7223633 | 0.76 | MAPT (0.42) | CA2CA1USP2TSHRMAPK1 | |
| SCHEMBL6789651 | 0.76 | TSHR (0.48) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650341-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-16 | — | — | US | disclosed |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | CA2 205/4885CA1 377/4885USP2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.